HRT Over 60: Is Hormone Replacement Therapy Safe?

Dr. Shweta Patel, MD, FACOG

Board-certified OB/GYN • U.S. Navy veteran (13 years) • Author, The Book of Hormones • Founder, Gaya Wellness

Published July 29, 2025 • Updated May 3, 2026

When a woman asks me, “Is HRT safe after 60?” I do not answer with a slogan. I start with triage.

Are we talking about a 61-year-old who started menopause hormone therapy at 52, feels well, has normal blood pressure, updated breast screening, no abnormal bleeding, and wants to continue? Or are we talking about a 68-year-old who has been off hormones for 15 years and now wants systemic estrogen for sleep, weight gain, and hot flashes? Those are not the same clinical situation.

This is where menopause care gets sloppy. Women are told either “too late, never” or “the warnings were wrong, everyone should consider it.” Both miss the point. Hormone therapy after 60 can be appropriate, but safety depends on timing, route, dose, uterus status, symptoms, medical history, and what problem we are actually treating.

The NAMS 2022 Hormone Therapy Position Statement frames this clearly: the benefit-risk ratio is generally more favorable for women younger than 60 or within 10 years of menopause onset, and less favorable when systemic therapy is initiated after 60 or more than 10 years from menopause because absolute risks rise with age and time. That does not mean every woman over 60 must stop. It means the plan needs more precision.

Start With the Real Question: Starting, Continuing, or Switching?

The first safety question is not “HRT or no HRT?” It is: what are we doing?

Continuing an effective, monitored plan after 60 is different from starting systemic hormone therapy for the first time after 60. Switching from oral estrogen to transdermal estradiol is different from raising a dose. Adding low-dose vaginal estrogen for painful sex or recurrent urinary symptoms is different from systemic therapy for hot flashes and night sweats.

If you have been stable on menopause hormone therapy for years, the discussion is usually about whether your benefits still outweigh your risks, whether your route remains appropriate, and whether the dose is still the lowest effective amount. If you are starting for the first time after 60, I want a more careful cardiovascular, clotting, breast, uterine, liver, migraine, and medication review before I prescribe anything.

This distinction matters because many women are frightened into stopping therapy abruptly at 60 or 65, even when their symptoms return severely and their original risk profile was favorable. Other women are started casually after a long gap without enough screening. Both are poor care.

Red Flags That Need Evaluation Before HRT Over 60

Before systemic hormone therapy after 60, I want to know what would make the plan higher risk or inappropriate without more workup. Red flags include unexplained vaginal bleeding, a personal history of breast cancer, prior blood clot, stroke, heart attack, active liver disease, uncontrolled hypertension, high-risk migraine patterns, complex clotting history, or missing breast screening.

Unexplained bleeding deserves special attention. Postmenopausal bleeding is never something to “watch” casually while starting hormones. It needs evaluation of the uterine lining first. If a woman has a uterus and uses systemic estrogen, she generally needs adequate progesterone or another endometrial-protective strategy. Estrogen without uterine protection can stimulate the lining and increase endometrial cancer risk.

Red flags do not always mean hormones are impossible. They mean the plan cannot be casual. A woman with controlled blood pressure may be managed differently from a woman with uncontrolled hypertension. A woman with a family history of breast cancer is not the same as a woman with a personal history of estrogen-sensitive breast cancer. A woman with vaginal dryness may be a candidate for local therapy even when systemic therapy is not a good fit.

This is why I do not like checklist medicine. A checklist catches danger. It does not replace judgment.

Route Is One of the Biggest Safety Levers

When women say “HRT,” they usually mean one thing. Clinically, route changes the conversation.

Oral estrogen passes through the liver first. Transdermal estradiol, such as a patch, gel, or spray, bypasses first-pass liver metabolism. That route difference can matter for clotting factors, triglycerides, inflammation markers, blood pressure patterns, gallbladder risk, and migraine counseling. The American College of Obstetricians and Gynecologists notes that systemic hormone therapy is associated with a small risk of stroke and blood clots, and that patches, sprays, and rings may pose less risk than pills.

That does not make transdermal estrogen risk-free. It means route selection is a safety tool. For many women over 60 who are candidates for systemic therapy, I would rather discuss transdermal estradiol than default to oral estrogen. I also want to know whether progesterone is needed, what type is being used, and whether bleeding is being tracked.

For genitourinary symptoms, the route may be even more important. A woman with vaginal dryness, painful sex, urinary urgency, or recurrent urinary tract symptoms may not need systemic estrogen at all. Low-dose vaginal estrogen is usually considered separately because systemic absorption is low and the treatment target is local tissue health. At Gaya, women often arrive asking for “HRT” when what they actually need is careful treatment for menopause hormone symptoms, vaginal tissue changes, or both.

Timing Changes the Risk Conversation

Timing is not ageism. It is vascular biology.

Starting systemic hormone therapy near menopause is not the same as starting it 15 or 20 years later. Blood vessels, plaque burden, clot risk, blood pressure, insulin resistance, and baseline disease risk change over time. That is why the “under 60 or within 10 years of menopause” window appears repeatedly in menopause guidance.

The Mayo Clinic summarizes the practical point for patients: if hormone therapy starts at age 60 or older, or more than 10 years since menopause, the risk of serious complications increases; if it starts before 60 or within 10 years, benefits may outweigh risks for appropriate candidates. That is a population-level statement, not a personal verdict.

For the woman in front of me, timing becomes part of the triage. How long since her final period? Did symptoms start recently or never resolve? Did she have early menopause, surgical menopause, chemotherapy-induced ovarian failure, or years of untreated severe symptoms? Is the goal hot flash control, sleep restoration, bone protection, sexual comfort, or a vague hope of “anti-aging”?

I am much more cautious with new systemic therapy after 60 when the goal is broad optimization rather than clear symptom treatment. Hormones are medicine. Medicine needs an indication.

FDA Label Changes Help, but They Do Not Remove the Need for Triage

In February 2026, the FDA announced approved labeling changes to menopausal hormone therapy products, including removal of certain boxed-warning risk statements related to cardiovascular disease, breast cancer, and probable dementia from the agency’s most prominent warning language for the first batch of products. The FDA also described menopause hormone therapies as approved for moderate-to-severe hot flashes, vaginal dryness and discomfort, and prevention of bone loss.

The FDA update matters because old warning language often flattened the nuance. Women were afraid of all estrogen, in all routes, at all ages, for all indications. That was not accurate.

But the correction does not mean HRT is casual. It does not mean a woman over 60 should order hormones from an online form without a real review. It does not mean progesterone is optional if she has a uterus. It does not mean bleeding can be ignored. It does not mean breast screening no longer matters. And it definitely does not mean every symptom after 60 is an estrogen deficiency problem.

The right response to the FDA label changes is not hype. It is better informed consent.

What I Want Women Over 60 to Ask Before Saying Yes

If you are over 60 and considering HRT, ask better questions than “Is it safe?” Ask:

• Am I starting, continuing, restarting, or switching? Each has a different risk conversation.
• What symptom are we treating? Hot flashes, sleep disruption, vaginal symptoms, urinary symptoms, bone loss, and mood changes do not require the same plan.
• Do I need systemic therapy? Local vaginal estrogen may be enough for local symptoms.
• Why this route? Oral, transdermal, and vaginal estrogen are not interchangeable safety decisions.
• Do I need progesterone? If you have a uterus and use systemic estrogen, uterine protection matters.
• What would make us stop or change course? Bleeding, headaches, breast changes, blood pressure changes, lack of benefit, or new diagnoses should trigger reassessment.

I also want women to ask what else could be contributing. Poor sleep can come from hot flashes, but also sleep apnea, thyroid disease, medications, alcohol, anxiety, pain, and glucose swings. Weight gain can overlap with menopause, but also insulin resistance, muscle loss, stress physiology, medications, and under-treated thyroid disease. In perimenopause and menopause, symptoms rarely live in one neat box.

How Gaya Builds a Safer Hormone Plan

Inside Hormonal Agency™, we do not treat HRT over 60 like a reflex refill or a forbidden category. We treat it like medicine.

That means we review symptoms, menopause timing, prior hormone exposure, uterus status, bleeding history, mammogram status, blood pressure, clot history, migraine pattern, metabolic markers, medications, family history, sexual health, sleep, mood, and goals. Sometimes the safest plan is transdermal estradiol with appropriate progesterone and follow-up. Sometimes it is vaginal estrogen only. Sometimes it is a nonhormonal medication, pelvic floor referral, thyroid workup, metabolic support, or coordination with Weight Loss Concierge.

For women who need a broader view of aging, muscle, bone, metabolism, and sexual health, we may also connect hormone decisions with longevity medicine. The goal is not to make every woman take hormones. The goal is to stop making women choose between outdated fear and reckless access.

If you are over 60 and suffering, you deserve a clinician who can hold nuance. You deserve someone who can say, “Let's evaluate this carefully,” instead of “Absolutely never” or “Sure, here is a script.”

Dr. Shweta Patel, MD, FACOG

Board-certified OB/GYN, U.S. Navy veteran, and founder of Gaya Wellness. Dr. Patel leads physician-managed programs in hormone optimization and longevity-focused care for women in midlife and beyond.

You have not failed. Your plan did.